**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 6016**

**Columns: SYSTEMATIC REVIEWS**

**Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases**

Mirnezami R *et al.* Multimodal treatment of colorectal peritoneal metastases

Reza Mirnezami, Brendan J Moran, Kate Harvey, Tom Cecil, Kandiah Chandrakumaran, Norman Carr, Faheez Mohamed, Alexander H Mirnezami

**Reza Mirnezami,** Section of Biosurgery and Surgical Technology, Department of Surgery and Cancer, Imperial College London, 10th Floor QEQM Building, St Mary’s Hospital, London W2 1NY, United Kingdom

**Brendan J Moran, Kate Harvey, Tom Cecil, Kandiah Chandrakumaran, Faheez Mohamed,** National Pseudomyxoma Peritonei Centre, Hampshire Hospitals Foundation Trust, Basingstoke RG24 9NA, United Kingdom

**Norman Carr, Alexander H Mirnezami,** Somers Cancer Research Building, University of Southampton Cancer Sciences Division, Southampton University Hospital NHS Trust, Southampton SO166YD, United Kingdom

**Supported by** Cancer Research United Kingdom; Wessex Medical Research

**Author contributions:** Mirnezami R, Moran BJ, Mohamed F, Mirnezami AH, study conception, literature search and manuscript preparation; Harvey K manuscript preparation; Cecil T manuscript preparation and manuscript editing; Chandrakumaran K manuscript preparation and manuscript editing; Carr N manuscript preparation and manuscript editing.

**Correspondence to: Dr. Alexander H Mirnezami,** Somers Cancer Research Building, University of Southampton Cancer Sciences Division, Southampton University Hospital NHS Trust, Tremona Road, Southampton SO166YD, United Kingdom. ahm@soton.ac.uk

**Telephone**: +44-2380-795170 **Fax:** +44-2380-794020

**Received:** September 29, 2013 **Revised:** December 16, 2013

**Accepted:** June 26, 2014

**Published online:**

**Abstract**

**AIM:** To systematically review the available evidence regarding cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) for colorectal peritoneal metastases (CPM).

**METHODS:** An electronic literature search was carried out to identify publications reporting oncological outcome data (overall survival and/or disease free survival and/or recurrence rates) following CRS and IPC for treatment of CPM. Studies reporting outcomes following CRS and IPC for cancer subtypes other than colorectal were only included if data were reported independently for colorectal cancer-associated cases; in addition studies reporting outcomes for peritoneal carcinomatosis of appendiceal origin were excluded.

**RESULTS:** Twenty seven studies, published between 1999 and 2013 with a combined population of 2838 patients met the predefined inclusion criteria. Included studies comprised 21 case series, 5 case-control studies and 1 randomised controlled trial. Four studies provided comparative oncological outcome data for patients undergoing CRS in combination with IPC versus systemic chemotherapy alone. The primary indication for treatment was CPM in 96% of cases (2714/2838) and recurrent CPM (rCPM) in the remaining 4% (124/2838). In the majority of included studies (20/27) CRS was combined with hyperthermic intraperitoneal chemotherapy (HIPEC). In 3 studies HIPEC was used in combination with early post-operative intraperitoneal chemotherapy (EPIC), and 2 studies used EPIC only, following CRS. Two studies evaluated comparative outcomes with CRS + HIPEC versus CRS + EPIC for treatment of CPM. The delivery of IPC was performed using an “open” or “closed” abdomen approach in the included studies.

**CONCLUSION:** The available evidence presented in this review indicates that enhanced survival times can be achieved for CPM after combined treatment with CRS and IPC.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Colorectal cancer; Peritoneal metastasis; Cytoreductive surgery;Intraperitoneal chemotherapy; Hyperthermic intraperitoneal chemotherapy

**Core tip:** Colorectal cancer peritoneal metastases (CPM) confer a dismal prognosis and traditional treatment involving systemic chemotherapy, with or without palliative surgery has poor outcomes. Cytoreductive surgery (CRS) combined with intraperitoneal chemotherapy (IPC) is now advocated for selected patients with CPM. The present study provides a comprehensive summary of the available evidence relating to CRS in combination with IPC in the setting of CPM, focusing on techniques, oncological outcomes, and complications.

Mirnezami R, Moran BJ, Harvey K, Cecil T, Chandrakumaran K, Carr N, Mohamed F, Mirnezami AH. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Colorectal cancer (CRC) is a major cause of cancer-associated mortality world-wide with over 1 million new cases diagnosed annually[[1](#_ENREF_1)]. Disseminated disease represents the principal cause of mortality in CRC and a significant proportion of patients are found to have locally advanced or systemically disseminated disease at initial presentation. It is estimated that at the time of diagnosis 30%-40% have locally advanced disease (Stage II-III) and approximately 20% have distant metastases (Stage IV)[[2](#_ENREF_2),[3](#_ENREF_3)]. Haematogenous spread to the liver is the most common route for distant-organ dissemination, followed by pulmonary metastases[[4](#_ENREF_4)]. Historically, patients with stage IV disease have been offered supportive therapy only, with 5-year survival rarely exceeding 5%[[5](#_ENREF_5" \o "Poon, 1989 #3190)]. Over the past two decades the widespread use of newer chemotherapeutic agents such as irinotecan and oxaliplatin, as well as novel targeted therapies, have led to a significant improvement in progression-free and overall survival in stage IV CRC[[6](#_ENREF_6),[7](#_ENREF_7)]. In parallel there has been sharp increase in the volume of surgical resections/ablative procedures being undertaken for stage IV disease, and curative intent hepatic and pulmonary metastasectomy are now routinely performed[[8](#_ENREF_8),[9](#_ENREF_9)].

Synchronous peritoneal carcinomatosis is identified at primary surgery in approximately 5%-10% of patients undergoing CRC resection[[10-12](#_ENREF_10" \o "Sadeghi, 2000 #3185)]. Additionally up to 20%-50% of patients undergoing curative intent colorectal cancer resection can go on to develop disease recurrence limited to the peritoneal cavity[[10](#_ENREF_10)]. In theory, the development of colorectal peritoneal disease starts with primary tumour rupture or invasion through the serosa, followed by seeding of free intra-peritoneal tumour cells[[13](#_ENREF_13)]. The precise mechanistic principles that govern distribution within the peritoneal cavity are multifactorial and have been well described and referred to as “redistribution phenomena“[[14](#_ENREF_14),[15](#_ENREF_15)]. Briefly, these factors include gravitational pooling of cancer-cell containing fluid in the pelvis, clockwise directional flow of peritoneal fluid in the abdominal cavity leading to sub-phrenic implantation[[16](#_ENREF_16)], and phagocytic activity of the greater and lesser omentum which leads to the formation of characteristic ‘omental cake’ deposits[[16-18](#_ENREF_16)].

The presence of peritoneal disease in the context of CRC confers a dismal prognosis, and traditional treatment involving systemic chemotherapy, with or without palliative surgery (typically reserved for acute complications such as intestinal obstruction) is associated with a median survival of 5-7 mo[[10-12](#_ENREF_10)]. Since the 1990s however, several pioneering groups around the world have sought to employ more radical strategies for the treatment of peritoneal surface malignancy. Cytoreductive surgery (CRS), popularised by Sugarbaker initially for relatively non-invasive tumours such as Pseudomyxoma Peritonei[[19](#_ENREF_19),[20](#_ENREF_20)], is now offered to selected patients at specialist units for what is best termed “Colorectal peritoneal metastases (CPM)”, analogous to the concept of resectable liver metatases[[21](#_ENREF_21)]. The aim of CRS is to remove all macroscopic disease through peritonectomy and multi-visceral resections where required. The extensiveness of these approaches varies according to cancer volume and anatomical location; CPM involving visceral peritoneal surfaces requires organ resection at times[[13](#_ENREF_13),[19](#_ENREF_19)], while treatment of disease confined to the parietal peritoneum involves more limited regional peritoneal stripping[[20](#_ENREF_20)].

The combination of these surgical approaches with peri-operative intra-peritoneal chemotherapy (IPC) has been advocated in order to eradicate residual cancer cells after macroscopic cytoreduction[[22](#_ENREF_22)]. The peritoneal route of chemotherapy is based on the peritoneal-plasma partition concept whereby a high concentration of the chemotherapy is in direct contact with cancerous cells with minimal systemic absorption and side effects. A variety of strategies have been proposed and investigated including hyperthermic intraperitoneal chemotherapy (HIPEC)[[23](#_ENREF_23),[24](#_ENREF_24)] and early post-operative intraperitoneal chemotherapy (EPIC)[[25](#_ENREF_25)]. The rationale for this combination in favour of systemic therapy alone stems from the understanding that reducing tumour burden represents a critical factor in achieving tumour response to chemotherapy[[13](#_ENREF_13)]. This notion is supported by the findings of a Dutch randomized-controlled trial (RCT) which reported significantly improved survival outcomes with CRS and HIPEC compared with systemic chemotherapy alone for patients with CPM[[26](#_ENREF_26)]. Despite these encouraging reports, the otherwise lack of level-1 evidence and concerns with respect to peri-operative morbidity, mortality, quality of life, and healthcare related costs, have polarised opinions regarding these aggressive multi-modality approaches, and the management of CPM remains controversial[[21](#_ENREF_21)].

To date there has been only one systematic review and meta-analysis of data regarding the utility of CRS and IPC in the context of CPM[[27](#_ENREF_27)]. Published in 2009, this study included a significant body of literature reporting data on peritoneal malignancy of appendiceal origin also. As the prognosis of peritoneal disease from appendiceal tumours is more favourable compared with CRC, we believe this to be a significant limitation[[28](#_ENREF_28" \o "Sugarbaker, 1995 #3239)].

The present study therefore aims to provide an up-to-date systematic review of the available literature regarding the use of CRS in combination with intra-peritoneal chemotherapy for treatment of CPM specifically. In particular, we focus on the current techniques, oncological outcomes, and associated complications.

**MATERIALS AND METHODS**

***Identification of studies***

An electronic literature search was carried out using the following medical subject heading (MeSH) terms: “colorectal cancer”; “peritoneal”; “carcinomatosis”; “cytoreductive surgery”; “chemotherapy”; “intra-operative”; “intra-peritoneal”. The “related articles” function was used to broaden search output. All potentially eligible publications were obtained in full text and assessed for suitability. Text references were manually searched for identification of additional eligible studies.

***Study inclusion criteria and data extraction***

Review methodology was conducted according to guidelines outlined in the “*Preferred Reporting Items for Systematic Reviews and Meta-Analyses* (PRISMA)” framework[[29](#_ENREF_29)]. Identified publications had to meet the following criteria to be included in the systematic review process: (1) English language; (2) ≥15 male/female adult patients (≥18 years); (3) histologically verified diagnosis of CPM receiving multi-modality treatment with CRS and IPC. Studies reporting outcomes following CRS and IPC for cancer subtypes other than colorectal were only included if survival outcome data were reported independently for CRC-associated cases; in addition studies reporting outcomes in patients undergoing treatment for peritoneal disease of appendiceal origin were excluded, as there is significant variation in the natural history and prognosis of this sub-group of patients[[28](#_ENREF_28)]; and (4) reporting oncological outcome data (survival and/or recurrence rates). Complication related data was also extracted where provided. Where multiple studies with potentially overlapping patient populations were identified, the most recent study was included. Figure 1 summarizes the review search strategy. Two reviewers (RM and AHM) derived the following data from eligible publications: author, location, year of publication and study timeframe, study type, population characteristics, primary or recurrent disease, stage of CPM (peritoneal cancer index (PCI)[[30](#_ENREF_30)] or alternative scoring method for disease extent), chemotherapeutic regimen, details of previous treatment (chemotherapy/radiotherapy), length of follow-up, treatment associated morbidity and mortality, completeness of cytoreduction (completeness of cytoreduction (CCR) score[[31](#_ENREF_31)] and/or R-classification where reported), oncological data (survival and/or recurrence rates). Studies that met inclusion criteria were evaluated based on methodological quality and validity using the Scottish Intercollegiate Guidelines Network (SIGN) framework[[32](#_ENREF_32)].

**RESULTS**

***Literature search and description of studies***

Initial literature searching identified 265 publications of potential relevance. From these 57 reviews and 118 irrelevant studies were excluded, leaving 90 articles retrieved in full text. Manual reference searches from these articles revealed an additional 3 potentially eligible publications, providing a total of 93 articles. Of these, 66 failed to meet inclusion criteria and were withdrawn after full text appraisal, leaving 27 studies (1999-2013) for systematic review (Figure 1). The combined number of patients with CPM in these studies was 2838 (range 18-523), of whom 2683 (95%) underwent combined modality treatment involving CRS and IPC. The remaining 155 patients (5%) received systemic chemotherapy alone. Studies included in the review comprised 21 case series[[17](#_ENREF_17),[33-52](#_ENREF_33)] (evidence level 3), 5 case-control studies[[53-57](#_ENREF_53)] (evidence level 2-) and 1 randomised controlled trial[[26](#_ENREF_26)] (evidence level 1-). Four studies provided comparative oncological outcome data for patients undergoing CRS in combination with IPC versus systemic chemotherapy alone[[26](#_ENREF_26),[53-55](#_ENREF_53)]. The primary indication for treatment was CPM in 96% of cases (2714/2838) and recurrent CPM (rCPM) in the remaining 4% (124/2838). Table 1 provides a summary of study design, treatment indications and treatment protocols for studies included in the systematic review process.

***Patient selection***

All studies defined first-time treated or recurrent CPM as the primary indication for treatment. Patient selection characteristics with respect to consideration for CRS +/- IPC were stated as follows: ***Inclusion criteria:*** (1) CPM of colorectal origin[[17](#_ENREF_17),[26](#_ENREF_26),[33-57](#_ENREF_33)]; (2) Adequate resection deemed technically feasible based on pre-operative imaging[[34](#_ENREF_34),[55](#_ENREF_55),[57](#_ENREF_57)]; and (3) Normal marrow indices/renal function/liver function pre-operatively[[26](#_ENREF_26),[34](#_ENREF_34),[36](#_ENREF_36),[43](#_ENREF_43),[47](#_ENREF_47),[50](#_ENREF_50)[56](#_ENREF_56)].

**Exclusion criteria:** (1) Evidence of extra-abdominal disease on pre-operative imaging[[17](#_ENREF_17),[33-38](#_ENREF_33),[43-45](#_ENREF_43),[47](#_ENREF_47),[48](#_ENREF_48),[50-54](#_ENREF_50),[56](#_ENREF_56),[57](#_ENREF_57)]; (2) Evidence of liver metastases on pre-operative imaging[[26](#_ENREF_26),[34-37](#_ENREF_34),[44](#_ENREF_44),[48](#_ENREF_48),[51](#_ENREF_51),[53](#_ENREF_53),[55](#_ENREF_55), [57](#_ENREF_57)]; (3) Advanced age (>71 years;[[26](#_ENREF_26), [36](#_ENREF_36)] >70 years;[[37](#_ENREF_37),[44](#_ENREF_44),[47](#_ENREF_47)] > 75 years[[46](#_ENREF_46), [50](#_ENREF_50), [53](#_ENREF_53)]; > 80[[17](#_ENREF_17)]; > 66[[54](#_ENREF_54)]); and (4) Significant medical co-morbidity[[34](#_ENREF_34),[43](#_ENREF_43),[44](#_ENREF_44),[46](#_ENREF_46),[47](#_ENREF_47),[51](#_ENREF_51),[52](#_ENREF_52),[55-57](#_ENREF_55)]. In the case of the latter criterion, 3 studies used the WHO performance score to determine suitability for aggressive treatment (≥ 2 excluded)[[47](#_ENREF_47),[56](#_ENREF_56),[57](#_ENREF_57)] and 3 studies used the Eastern Cooperative Oncology Group (ECOG) Performance Status metric[[58](#_ENREF_58)] (≥ 2 excluded)[[46](#_ENREF_46),[51](#_ENREF_51),[52](#_ENREF_52)]. The remaining 4 studies did not use any formal method for functional assessment[[34](#_ENREF_34),[43](#_ENREF_43),[44](#_ENREF_44),[55](#_ENREF_55)]. None of the identified studies performed formal assessment of functional capacity using cardiopulmonary exercise testing.

***Techniques used for IPC***

In the majority of included studies (20/27) CRS was combined with HIPEC[[17](#_ENREF_17),[26](#_ENREF_26),[34-37](#_ENREF_34),[39-44](#_ENREF_39),[46-48](#_ENREF_46),[50-52](#_ENREF_50),[54](#_ENREF_54),[55](#_ENREF_55)]. In 3 studies HIPEC was used in combination with EPIC[[37](#_ENREF_37),[45](#_ENREF_45),[49](#_ENREF_49)], and 2 studies used EPIC only following cytoreduction[[33](#_ENREF_33),[53](#_ENREF_53)]. Two studies were specifically designed to assess comparative outcomes with CRS + HIPEC *vs* CRS + EPIC for treatment of CPM[[56](#_ENREF_56),[57](#_ENREF_57)].

The delivery of IPC was performed using an “open” or “closed” abdomen approach in the included studies. The open approach was generally performed using the Coliseum technique, as proposed by Sugarbaker (Figure 2A)[[59](#_ENREF_59)]. Briefly, this involves placement of a Tenckhoff catheter and four closed suction drains through the abdominal wall before the skin edges are suspended with a running suture to a Thompson self-retaining retractor, creating an open cavity for IPC delivery. Typically, IPC is pumped into the open abdomen via the Tenckhoff catheter for between 30-90 min at a temperature of 41-43°C. This fluid is then circulated back out of the abdomen via the four suction drains. The main advantage with this technique is that IPC is distributed evenly throughout the abdomen, though heat dissipation makes it more time consuming to reach the required temperature. With the closed technique catheters are introduced before the laparotomy wound is sutured and perfusion is carried out via a closed circuit, with the abdominal wall manually agitated to facilitate even distribution of IPC and temperature (Figure 2B). After adequate perfusion, the abdominal wound is opened in order to evacuate the IPC before re-closure. An advantage with this method is the ability to rapidly achieve the required temperature, as heat dissipation is minimized.

***Oncological outcomes***

Oncological outcome data from the 27 studies included in this review are summarised in Table 2. Median survival ranged from 3.7 to 62.7 mo and showed strong correlation with completeness of cytoreduction (as determined by CCS score or R-classification). To date there has been only one RCT carried out to compare outcomes with CRS + HIPEC and conventional systemic chemotherapy alone for treatment of CPM[[26](#_ENREF_26" \o "Verwaal, 2008 #3224)]. This study included 105 patients randomly assigned to receive either IV 5-FU or experimental treatment which consisted of an aggressive multimodality approach incorporating CRS combined with HIPEC using mitomycin C. After a median follow up time of 96 mo the authors reported median survival of 22.2 mo in the CRS + HIPEC group compared with 12.6 mo in patients receiving chemotherapy alone[[26](#_ENREF_26)]. Three case-control studies provided non-randomized comparative data evaluating the impact of aggressive treatment on survival for patients with CPM. Mahteme *et al*[[53](#_ENREF_53" \o "Mahteme, 2004 #3256)] reported outcomes in 18 patients undergoing CRS + EPIC compared with 18 age and gender matched patients receiving chemotherapy only. This study reported overall 2- and 5-year survival of 60% and 28% in the CRS + EPIC group compared with 10% and 5% respectively in the chemotherapy group. Median survival for patients undergoing complete cytoreduction (CC0) was 32 mo compared with 14 months in the control group. A 2009 study by Elias and colleagues reported similarly improved survival with aggressive multi-modality treatment; here the authors compared survival data from 48 patients undergoing CRS + HIPEC with 48 receiving chemotherapy alone[[54](#_ENREF_54)]. Median survival, 2- and 5-year survival were all superior in the CRS + HIPEC treatment group (62.7 months, 81% and 51%) compared with the chemotherapy group (23.9 mo, 65% and 13%). Franko *et al*[[55](#_ENREF_55)]reported outcomes of a case-control study of 105 patients with CPM in which 67 underwent CRS + HIPEC and 38 received systemic chemotherapy only. The authors reported 1-, 3- and 5- year survival of 90%, 50% and 25% in the CRS + HIPEC group compared with 55%, 12% and 7% in the control group.

***Complications***

Treatment-associated mortality ranged from 0 to 12% in the included studies and overall morbidity was high, ranging from 21.8%-62%. Five of the studies did not provide any morbidity data[[26](#_ENREF_26),[33](#_ENREF_33),[36](#_ENREF_36),[54](#_ENREF_54),[55](#_ENREF_55)] and in two studies complications were not reported specifically for patients being treated for CPM[[45](#_ENREF_45),[51](#_ENREF_51)]. Specific complications and their incidence are presented in Table 3. The most commonly encountered surgical complications were wound associated problems (infection/dehiscence, 3%-12%)[[34](#_ENREF_34),[40-44](#_ENREF_40),[49](#_ENREF_49)] fistulae (intestinal/pancreatic/urinary, 1%-11%)[[17](#_ENREF_17),[37](#_ENREF_37),[38](#_ENREF_38),[41-44](#_ENREF_41),[46-50](#_ENREF_46)] and intra-abdominal abscess formation (1.8-14%)[[17](#_ENREF_17),[38](#_ENREF_38),[41](#_ENREF_41),[42](#_ENREF_42),[44](#_ENREF_44),[46](#_ENREF_46),[48](#_ENREF_48)] The re-operation rate reported from all studies ranged from 4% to 20.8%. Haematological toxicity as a result of chemotherapy was reported with an incidence of 2% to 52%[[34](#_ENREF_34),[35](#_ENREF_35),[38](#_ENREF_38),[39](#_ENREF_39),[43](#_ENREF_43),[44](#_ENREF_44),[48](#_ENREF_48),[50](#_ENREF_50),[53](#_ENREF_53)].

**DISCUSSION**

Peritoneal metastasis from colorectal cancer (CPM), either at initial presentation, or at subsequent recurrence, presents significant challenges. The majority of patients have extensive disease (correctly labelled colorectal carcinomatosis; Figure 3A), and are not amenable to curative surgical intervention. A proportion, best categorized as Colorectal Peritoneal Metastasis (CPM) (Figure 3B and C) can be treated with curative intent by a combination of CRS and IPC. Without treatment, practically all patients with cancer spread to the peritoneum have poor outcomes, exceptionally impaired quality of life, and abbreviated survival. Conventional surgical resection alone has not been demonstrated to be effective for treatment of CPM, and is associated with a median survival of less than 6 months.[60](#_ENREF_60) Similarly, orthodox systemic chemotherapy treatment for CPM has only limited efficacy, at least in part owing to the plasma-peritoneal barrier which results in decreased intra-peritoneal drug penetration.

For all these reasons, aggressive multidisciplinary treatment incorporating cytoreductive surgical (CRS) techniques and intra-peritoneal chemotherapy has been proposed and pursued as a logical treatment strategy to improve long-term survival, and may represent an appealing and natural evolution of the management of complex and advanced CRC.

Historically, this form of radical approach has been rarely applied owing to concerns regarding high morbidity and mortality. In more recent times however, advances in radiological staging and surgical and anaesthetic practice, improved experience in chemotherapeutic methods, and better management of associated toxicity, have helped expand the treatment options for patients with peritoneal disease, allowing enhanced prognosis and survivorship through increased application of CRS and IPC. However, despite a recent consensus statement published on the role of CRS in combination with HIPEC in the management of CPM[[24](#_ENREF_24)], there is on-going disagreement and controversy regarding the precise role of this multimodality approach in treatment algorithms, and firm evidence to support widespread implementation has been questioned.

The purpose of the present review was to systematically and critically analyse the available literature. Twenty seven studies with a combined population of 2838 patients met the predefined inclusion criteria and were included in the review process. Only publications in the last 15 years were included to eliminate any time-dependant bias from subtle alterations to treatment approaches and drugs. The available literature consists mainly of low-grade evidence with small case series or comparative studies, with the exception of one relatively recent randomised trial. Furthermore, there is substantial between-study heterogeneity, non-standardised definitions, and inconsistent reporting of data. In spite of these limitations, this body of data clearly indicates that the greatest survival times from CPM are achieved after treatment in specialist institutions by CRS and IPC, with a predictable high, but perhaps acceptable, frequency of complications. The exact nature and location of re-recurrence was reported in few studies, with disease recurring in the peritoneal compartment (ranging from 28%-59%); in distant organs alone (12%-17%); or in both peritoneal and distant organs (18%-28%; Table 2).

One key consideration is the selection of patients for radical treatment strategies. The studies included in this review illustrate a wide variety of methods with no overall consensus or approach. While a number of studies stated medical co-morbidity as one exclusion criterion, this was generally poorly defined. Cardiopulmonary exercise testing is one of the most reliable methods of risk prediction in non-cardiopulmonary surgical procedures, outperforming alternative methods of risk stratification, and can readily aid in identification of patients at an increased risk of adverse perioperative events.[61](#_ENREF_61) No studies included in the present review used formal pre-operative cardiopulmonary exercise testing as a risk stratification measure however. Similarly, while some authors would consider the presence of other solid organ metastases on pre-operative imaging to be a contraindication to CRS and PIC[[26](#_ENREF_26),[34-37](#_ENREF_34),[42](#_ENREF_42),[44](#_ENREF_44),[48](#_ENREF_48),[51](#_ENREF_51),[53](#_ENREF_53),[55](#_ENREF_55),[57](#_ENREF_57)] this is not an absolute if other metastases are resectable[[38](#_ENREF_38)]. Further stratification factors are the extent of disease, and the ability to achieve a complete cytoreduction. Both are major predictors of oncological outcome, however significant variability was noted in the assessment methods used for the evaluation of disease extent in the studies examined. In 10 of the included studies a marked reduction in long-term survival was reported following CC2-3, compared with CC0-1 resection[[26](#_ENREF_26),[33](#_ENREF_33),[36-39](#_ENREF_36),[44](#_ENREF_44),[52](#_ENREF_52),[53](#_ENREF_53),[62](#_ENREF_62)]. In the largest study included in this review, analysis of outcomes in 506 patients treated with CRS and HIPEC found completeness of cytoreduction to be the strongest predictor of survival on multivariate analysis (*P* < 0.0001)[[38](#_ENREF_38)]. The authors of this study also found extent of disease at time of surgery (PCI) to be a significant determinant of survival (*P*<0.001)[[38](#_ENREF_38)] This finding is supported by the results of Quenet *et al*[[46](#_ENREF_46)] who reported 5-year survival of 65%, 26% and 18% respectively for patients with PCI < 10, PCI 11-19 and PCI > 20. Other factors such as tumour differentiation[[17](#_ENREF_17),[35](#_ENREF_35),[38](#_ENREF_38),[52](#_ENREF_52), the presence of bowel obstruction[[39](#_ENREF_46)], malignant ascites[[39](#_ENREF_46)], age[[38](#_ENREF_46)] lymph node dissemination[[38](#_ENREF_46)] and extent of small bowel involvement[[52](#_ENREF_52)] have also been identified as negative prognostic indicators, and further investigation is required in order to better define the relative contributions of these factors to disease outcome.

The present systematic analysis is subject to a number of limitations. All but one of the studies were non-randomised, mainly with small sample sizes, and were heterogeneous with respect to extent of peritoneal disease and its manner of assessment; protocol and type of chemotherapy applied; and measured outcomes. Most were conducted in large tertiary referral cancer centres. Crucially, it is not possible to separate the incremental contribution of CRS and IPC from the available data, making it difficult to draw definitive conclusions regarding the individual contribution of each to the positive outcomes. Only one RCT has been undertaken to date comparing CRS and IPC with conventional systemic chemotherapy[[26](#_ENREF_26" \o "Verwaal, 2008 #3224)]. Verwaal *et al* found improved survival with CRS + HIPEC compared with systemic chemotherapy alone, though these findings are limited somewhat by the single institution nature of the study, the relatively modest sample size, and the fact that patients in the control arm received 5-FU, rather than more contemporary oxaliplatin-based therapy. Clearly therefore, the findings presented here must be interpreted within these limitations. Nevertheless, in view of the limited evidence base in this field at the present time, synthesised evidence in the present form represents the most informative means of evaluation.

A number of questions still remain. Better methods of patient selection are clearly required, and the role of physiological testing preoperatively may well merit further study to more effectively gauge functional capacity and risk of adverse events. In addition, an important challenge in the future will be to identify methods to avoid over-treatment in patients with chemotherapy insensitive tumours, and to limit side-effects in those with chemo-sensitive disease. The exact type of chemotherapy and its method of administration remain unclear at the present time, as is the precise contribution of CRS and IPC to the favourable outcomes observed. A further key question will be whether different/more radical/dose escalated IPC regimes can counter unfavourable peritoneal disease extent scores. Robust molecular biomarkers of oncological outcome and disease response are clearly required and are presently lacking. Exciting developments in the molecular sciences and the multi-platform high-throughput methods increasingly applied to diverse tumour types are transforming established treatment approaches, and offer the opportunity for the development of more personalised strategies in the treatment of CPM. Although no targeted therapeutic agents are currently approved for use in the treatment of CPM, it is expected that emerging tumour-targeted molecular therapies will permit more cancer-specific cytotoxicity, potentially enhancing oncological outcome and minimising unwanted toxicity.

In conclusion,Peritoneal disease from colorectal cancer remains a significant clinical problem and presents unique challenges and opportunities. The concept of resectable CPM is useful in this complex field. The present review indicates that the evidence base for CRS and IPC is composed largely of prospective and retrospective series with only one RCT on the subject to date. Nevertheless these studies appear to demonstrate survival rates greater than any available alternative, justifying an aggressive approach. Similar to acceptance of surgery for liver, lung, and occasionally brain metastatic CRC, radical treatment for peritoneal disease from CRC now has an established place in selected patients, offering the only realistic chance of long-term survival. In the future, high-number, multi-institutional studies with limited heterogeneity in assessment and treatment protocols may better enable clarification of some of the controversies in the treatment of CPM.

**COMMENTS**

***Background***

The finding of peritoneal surface malignancy in the context of colorectal cancer confers a dismal prognosis. Conventional treatment for this sub-group of patients involves systemic chemotherapy with or without palliative surgery. Multimodality treatment with cytoreductive surgery in combination with intraoperative chemotherapy is performed at specialist units around the world and can result in improved oncological outcome.

***Research frontiers***

The aim of CRS is to remove all macroscopic disease through peritonectomy and multi-visceral resections where required. The extensiveness of these approaches varies according to cancer volume and anatomical location. The combination of CRS with IPC has been advocated in order to eradicate residual cancer cells after macroscopic cytoreduction. In this study, the authors provide a Systematic Review of the available evidence regarding these multimodality treatment approaches.

***Innovations and breakthroughs***

Recent reports indicate that combined therapy involving CRS and IPC can result in improved oncological outcome and even long-term survival in patients with CPM, compared to conventional treatment. This study provides a comprehensive and up-to-date review of the available literature in this field.

***Applications***

Although subject to inherent methodological limitations, the studies included in this review appear to support the use of an aggressive multimodality treatment approach in the management of CPM.

***Terminology***

Cytoreductive surgery (CRS) refers to the macroscopic removal of peritoneal surface cancer deposits through peritoneal stripping procedures and/or visceral resection, depending on extent and location of carcinomatosis. Intraperitoneal chemotherapy is administered in combination with CRS as a means of eradicating residual tumour.

***Peer review***

The authors present a systematic review of the literature of cytoreductive surgery combined with intraperitoneal chemotherapy in colorectal cancer peritoneal metastasis. The authors spent a lot of efforts on the summary of clinical data from 27 studies. It has been reported the effectiveness of intraperitoneal chemotherapy in the patients with peritoneal metastasis. However, this kind of review work has not been reported. Therefore, I think this work has very high originality to contribute to our further clinical works.

**REFERENCES**

1 Available from: URL: http: //www.pelicancourses: coursedocs/PMP Workshop October 2013 Flyer 3 .pdf.

2 **O'Neil BH**, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. *Oncologist* 2008; **13**: 1074-1083 [PMID: 18922828 DOI: 10.1634/theoncologist.2008-0083]

3 **Wang CC**, Li J. An update on chemotherapy of colorectal liver metastases. *World J Gastroenterol* 2012; **18**: 25-33 [PMID: 22228967 DOI: 10.3748/wjg.v18.i1.25]

4 **Cunningham D**, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. *Lancet* 2010; **375**: 1030-1047 [PMID: 20304247 DOI: 10.1016/S0140-6736(10)60353-4]

5 **Poon MA**, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. *J Clin Oncol* 1989; **7**: 1407-1418 [PMID: 2476530]

6 **Cunningham D**, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004; **351**: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]

7 **Giantonio BJ**, Levy DE, O'dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. *Ann Oncol* 2006; **17**: 1399-1403 [PMID: 16873427 DOI: 10.1093/annonc/mdl161]

8 **Zdenkowski N**, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. *Oncologist* 2012; **17**: 201-211 [PMID: 22234631 DOI: 10.1634/theoncologist.2011-0300]

9 **Gonzalez M**, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. *Ann Surg Oncol* 2013; **20**: 572-579 [PMID: 23104709 DOI: 10.1245/s10434-012-2726-3]

10 **Sadeghi B**, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. *Cancer* 2000; **88**: 358-363 [PMID: 10640968]

11 **Jayne DG**, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. *Br J Surg* 2002; **89**: 1545-1550 [PMID: 12445064 DOI: 10.1046/j.1365-2168.2002.02274.x]

12 **Chu DZ**, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. *Cancer* 1989; **63**: 364-367 [PMID: 2910444 DOI: 3.0.CO; 2-V']

13 **Cotte E**, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O. Management of peritoneal carcinomatosis from colorectal cancer: current state of practice. *Cancer J* 2009; **15**: 243-248 [PMID: 19556911 DOI: 10.1097/PPO.0b013e3181a58d67]

14 **Esquivel J**, Sugarbaker PH. Clinical presentation of the Pseudomyxoma peritonei syndrome. *Br J Surg* 2000; **87**: 1414-1418 [PMID: 11044169 DOI: 10.1046/j.1365-2168.2000.01553.x]

15 **Zoetmulder FA**. Cancer cell seeding during abdominal surgery: experimental studies. *Cancer Treat Res* 1996; **82**: 155-161 [PMID: 8849949 DOI: 10.1007/978-1-4613-1247-5\_10]

16 **Kerscher A**, Esquivel J. Current status and future directions: management of colon cancer with peritoneal dissemination. *Future Oncol* 2008; **4**: 671-679 [PMID: 18922124 DOI: 10.2217/14796694.4.5.671]

17 **Yan TD**. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei: need to establish a multi-institutional registry. *Ann Surg* 2008; **247**: 556-557 [PMID: 18376211 DOI: 10.1097/SLA.0b013e31816617c9]

18 **Iitsuka Y**, Kaneshima S, Tanida O, Takeuchi T, Koga S. Intraperitoneal free cancer cells and their viability in gastric cancer. *Cancer* 1979; **44**: 1476-1480 [PMID: 498022 DOI: 3.0.CO; 2-R']

19 **Sugarbaker PH**. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. *Can J Surg* 1989; **32**: 164-170 [PMID: 2713770]

20 **Sugarbaker PH**. Peritonectomy procedures. *Ann Surg* 1995; **221**: 29-42 [PMID: 7826158 DOI: 10.1097/00000658-199501000-00004]

21 **Moran BJ**, Cecil TD. Treatment of surgically resectable colorectal peritoneal metastases. *Br J Surg* 2014; **101**: 5-7 [PMID: 24254364]

22 **Sugarbaker PH**, Landy D, Pascal R. Intraperitoneal chemotherapy for peritoneal carcinomatosis from colonic or appendiceal cystadenocarcinoma: rationale and results of treatment. *Prog Clin Biol Res* 1990; **354B**: 141-170 [PMID: 2236162]

23 **Moran BJ**, Meade B, Murphy E. Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery for peritoneal carcinomatosis of colorectal origin: a novel treatment strategy with promising results in selected patients. *Colorectal Dis* 2006; **8**: 544-550 [PMID: 16919104 DOI: 10.1111/j.1463-1318.2006.01050.x]

24 **Esquivel J**, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. *Ann Surg Oncol* 2007; **14**: 128-133 [PMID: 17072675]

25 **Sugarbaker PH**, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, Oliff L, Schlag P. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. *Cancer Res* 1990; **50**: 5790-5794 [PMID: 2118420]

26 **Verwaal VJ**, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. *Ann Surg Oncol* 2008; **15**: 2426-2432 [PMID: 18521686 DOI: 10.1245/s10434-008-9966-2]

27 **Cao C**, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. *Ann Surg Oncol* 2009; **16**: 2152-2165 [PMID: 19434455 DOI: 10.1245/s10434-009-0487-4]

28 . Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. *Ann Surg* 1995; **221**: 124-132 [DOI: 10.1097/00000658-199502000-00002]

29 **Moher D**, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009; **339**: b2535 [PMID: 19622551 DOI: 10.1136/bmj.b2535]

30 **Jacquet P**, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. *Cancer Treat Res* 1996; **82**: 359-374 [PMID: 8849962 DOI: 10.1007/978-1-4613-1247-5\_23]

31 **Sugarbaker PH**. Successful management of microscopic residual disease in large bowel cancer. *Cancer Chemother Pharmacol* 1999; **43** Suppl: S15-S25 [PMID: 10357554 DOI: 10.1007/s002800051093]

32 **Harbour R**, Miller J. A new system for grading recommendations in evidence based guidelines. *BMJ* 2001; **323**: 334-336 [PMID: 11498496 DOI: 10.1136/bmj.323.7308.334]

33 **Portilla AG**, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. *World J Surg* 1999; **23**: 23-29 [PMID: 9841759 DOI: 10.1007/s002689900560]

34 **Witkamp AJ,** de Bree E, Kaag MM, Boot H, Beijnen JH, van Slooten GW, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. *Eur J Cancer* 2001; **37**: 979-984 [DOI: 10.1016/S0959-8049(01)00058-2]

35 **Pilati P**, Mocellin S, Rossi CR, Foletto M, Campana L, Nitti D, Lise M. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. *Ann Surg Oncol* 2003; **10**: 508-513 [PMID: 12794016 DOI: 10.1245/ASO.2003.08.004]

36 **Verwaal VJ**, Boot H, Aleman BM, van Tinteren H, Zoetmulder FA. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. *Ann Surg Oncol* 2004; **11**: 375-379 [PMID: 15070596 DOI: 10.1245/ASO.2004.08.014]

37 **Glehen O**, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. *Br J Surg* 2004; **91**: 747-754 [PMID: 15164446 DOI: 10.1002/bjs.4473]

38 **Glehen O**, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. *J Clin Oncol* 2004; **22**: 3284-3292 [PMID: 15310771 DOI: 10.1200/JCO.2004.10.012]

39 **Shen P**, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, Levine EA. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. *Ann Surg Oncol* 2004; **11**: 178-186 [PMID: 14761921 DOI: 10.1245/ASO.2004.05.009]

40 **Cavaliere F**, Valle M, De Simone M, Deraco M, Rossi CR, Di Filippo F, Verzi S, Giannarelli D, Perri P, Pilati PL, Vaira M, Di Filippo S, Garofalo A. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study. *In Vivo* ; **20**: 747-750 [PMID: 17203760]

41 **Kianmanesh R**, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, Hay JM, Flamant Y, Msika S. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. *Ann Surg* 2007; **245**: 597-603 [PMID: 17414609 DOI: 10.1097/01.sla.0000255561.87771.11]

42 **Gusani NJ**, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. *Ann Surg Oncol* 2008; **15**: 754-763 [PMID: 18080166 DOI: 10.1245/s10434-007-9701-4]

43 **Varban O**, Levine EA, Stewart JH, McCoy TP, Shen P. Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases. *Cancer* 2009; **115**: 3427-3436 [PMID: 19499577 DOI: 10.1002/cncr.24385]

44 **Vaira M**, Cioppa T, D'Amico S, de Marco G, D'Alessandro M, Fiorentini G, De Simone M. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years. *In Vivo* 2010; **24**: 79-84 [PMID: 20133981]

45 **Glehen O**, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. *Cancer* 2010; **116**: 5608-5618 [PMID: 20737573 DOI: 10.1002/cncr.25356]

46 **Quenet F**, Goéré D, Mehta SS, Roca L, Dumont F, Hessissen M, Saint-Aubert B, Elias D. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. *Ann Surg* 2011; **254**: 294-301 [PMID: 21772129 DOI: 10.1097/SLA.0b013e3182263933]

47 **Passot G**, Vaudoyer D, Cotte E, You B, Isaac S, Noël Gilly F, Mohamed F, Glehen O. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. *Ann Surg* 2012; **256**: 125-129 [PMID: 22580942 DOI: 10.1097/SLA.0b013e318255486a]

48 **Hompes D**, D'Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Legendre H, Kerger J. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. *Ann Surg Oncol* 2012; **19**: 2186-2194 [PMID: 22395983 DOI: 10.1245/s10434-012-2264-z]

49 **Klaver YL**, Chua TC, de Hingh IH, Morris DL. Outcomes of elderly patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal cancer peritoneal carcinomatosis. *J Surg Oncol* 2012; **105**: 113-118 [PMID: 21780124 DOI: 10.1002/jso.22019]

50 **Turrini O**, Lambaudie E, Faucher M, Viret F, Blache JL, Houvenaeghel G, Delpero JR. Initial experience with hyperthermic intraperitoneal chemotherapy. *Arch Surg* 2012; **147**: 919-923 [PMID: 23117830 DOI: 10.1001/archsurg.2012.988]

51 **Haslinger M**, Francescutti V, Attwood K, McCart JA, Fakih M, Kane JM, Skitzki JJ. A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. *Cancer Med* 2013; **2**: 334-342 [PMID: 23930210 DOI: 10.1002/cam4.80]

52 **Yonemura Y**, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. *ScientificWorldJournal* 2013; **2013**: 978394 [PMID: 23710154 DOI: 10.1155/2013/978394]

53 **Mahteme H**, Hansson J, Berglund A, Påhlman L, Glimelius B, Nygren P, Graf W. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. *Br J Cancer* 2004; **90**: 403-407 [PMID: 14735184 DOI: 10.1038/sj.bjc.6601586]

54 **Elias D**, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. *J Clin Oncol* 2009; **27**: 681-685 [PMID: 19103728 DOI: 10.1200/JCO.2008.19.7160]

55 **Franko J**, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. *Cancer* 2010; **116**: 3756-3762 [PMID: 20564081 DOI: 10.1002/cncr.25116]

56 **Cashin PH**, Graf W, Nygren P, Mahteme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study. *Eur J Surg Oncol* 2012; **38**: 509-515 [PMID: 22475555 DOI: 10.1016/j.ejso.2012.03.001]

57 **Cashin PH**, Graf W, Nygren P, Mahteme H. Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study. *Ann Oncol* 2012; **23**: 647-652 [PMID: 21685413 DOI: 10.1093/annonc/mdr301]

58 **Oken MM**, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982; **5**: 649-655 [PMID: 7165009 DOI: 10.1097/00000421-198212000-00014]

59 **Stephens AD**, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. *Ann Surg Oncol* 1999; **6**: 790-796 [PMID: 10622509 DOI: 10.1007/s10434-999-0790-0]

60 **Mohamed F**, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. *Curr Oncol* 2011; **18**: e84-e96 [PMID: 21505593 DOI: 10.3747/co.v18i2.663]

61 **Hennis PJ**, Meale PM, Grocott MP. Cardiopulmonary exercise testing for the evaluation of perioperative risk in non-cardiopulmonary surgery. *Postgrad Med J* 2011; **87**: 550-557 [PMID: 21693573 DOI: 10.1136/pgmj.2010.107185]

62 **Yan TD**, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? *Ann Surg* 2008; **248**: 829-835 [PMID: 18948811]

**P-Reviewers:** Garrido-Laguna I, Izuishi K **S-Editor:** Qi Y

**L-Editor: E-Editor:**

**Figure 1 Modified Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram outlining study selection strategy.**



**Figure 2 Open (A) and closed (B) methods of intraperitoneal chemotherapy.**



**Figure 3 Widespread colorectal peritoneal carcinomatosis (A) compared to colorectal peritoneal metastasis on the parietal peritoneal surface (B, arrows) or on the peritoneum of the small bowel mesentry (C).**



**Table 1 Summary of study design, treatment indications and treatment protocols for studies included in systematic review process**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Time frame** | **N** | **Study design (evidence level)** | **Indication** | **Extent of CPM** | **Treatment summary** | **Technique** | **Intraperitoneal chemotherapeutic regimen** |
| Portilla *et al*[[33](#_ENREF_33)] | 1985-1996 | 18 | Case series (3) | rCPM1  | PCI < 12 10/18 (60%)PCI > 12 8/18 (38%) | CRS + EPIC | Closed technique | **POD 1:** MMC in 1L 1.5% dextrose peritoneal dialysis solution (10-12.5 mg/m2)**POD 2-6:** 5-FU in 1L 1.5% dextrose peritoneal dialysis solution + 50 mEq sodium bicarbonate |
| Witkamp *et al*[[34](#_ENREF_34)] | 1995-1997 | 29 | Case series (3) | CPM§ | - | CRS + HIPEC | Closed technique | MMC 35mg/m2 in 3-4 L of isotonic dialysis fluid at a temperature of 40-41°C for 90 min  |
| Pilati *et al* [[35](#_ENREF_35)] | 1995-2001 | 34 | Case series(3) | CPM§ | - | CRS + HIPEC | 10/34 closed technique14/34 open technique | MMC (3.3 mg/m2/L) + cisplatin (25 mg/m2/L) for 90 min at temperature of 41-42°C |
| Verwaal *et al* [[36](#_ENREF_36)]  | 1995-2003 | 106 | Case series(3) | rCPM§ | - | CRS + HIPEC | Closed abdomen technique | MMC 35mg/m2 in 3-4 L of isotonic dialysis fluid at a temperature of 40-41°C for 90 min  |
| Glehen *et al* [[37](#_ENREF_37)] | 1989-2002 | 53 | Multicentre case series (3) | CPM§ | Stage2 I 13/53 (25%) Stage II 8/53 (15%)Stage III 7/53 (13%)Stage IV 25/53 (47%) | CRS + HIPEC | Closed abdomen technique | MMC 40-60 mg in 4-6L of perfusate at a temperature of 46-48° for 90 min |
| Mahteme *et al* [[53](#_ENREF_53)]  | 1991-1999 | 36(18 *vs* 18) | Case-control (2-) | CPM§ | - | *Treatment arm:* CRS + EPIC (*n* = 18)*Control arm:*Systemic CT only(*n* = 18) | Closed abdomen technique | EPIC protocol:5-FU 550 mg/m2 in 500 mL normal saline administered intraperitoneally from POD 1. IV infusion of leucovorin (60 mg/m2) commenced at 60 min after initiation of PIC. Regimen offered 1-8 courses as tolerated with 4-6 wk interval between cycles. Systemic CT protocol: Chemotherapeutic regimen not specified |
| Glehen et al [[38](#_ENREF_38)]  | 1987-2002 | 506 | Multinational case series (3) | CPM¥ | Limited 171/506Extended 329/506 | CRS + HIPEC and/or EPIC  | Open or closed technique | *HIPEC protocol:* Various (MMC alone 274/506; MMC + cisplatin 48/506; oxaliplatin 32/506; other 29/506)*EPIC protocol:*Various (MMC alone 2/506; MMC + 5-FU 113/506; 5-FU alone 95/506; other 7/506)  |
| Shen *et al* [[39](#_ENREF_39)] | 1991-2002 | 77 | Case series (3) | CPM¥ | - | CRS + HIPEC | Closed abdomen technique | 40 mg MMC introduced into dialysis fluid for 120 min at ≥ 38.5°C  |
| Cavaliere *et al* [[40](#_ENREF_40)] | 1996-2005 | 120 | Multicentre case series (3) | CPM1 | - | CRS + HIPEC | Open 56.7%Closed 43.3% | 109/120: MMC (3.3 mg/m2/L) and cisplatin (25 mg/m2/L) at 41.5-43°C for 60-90 min11/120: oxaliplatin (460 mg/m2) for 30 min after IV 5-FU and leucovorin |
| Kianmanesh *et al*[[41](#_ENREF_41)]  | 1996-2006 | 43 | Case series (3) | CPM¥ | Stage2 I/II 10/43 (23%)Stage III 6/43 (14%)Stage IV 27/43 (63%) | CRS + HIPEC | Open technique | MMC 120 mg + cisplatin 200 mg/m2 at 41-43°C for 90 to 120 min |
| Gusani *et al*[[42](#_ENREF_42)] | 2002-2005 | 28 | Case series (3) | CPM§ | - | CRS + HIPEC | Closed technique | MMC 30-40mg in 3L saline solution at temperature of 40°C for 100 minutes |
| Verwaal *et al*[[26](#_ENREF_26)] | 1998-2001 | 105(54 *vs*.51) | Randomized trial (1-) | CPM§ | - | *Treatment arm:*CRS + HIPEC (*n* = 54)*Control arm:*Systemic CT only (*n* = 51)  | Open coliseum technique | *HIPEC protocol:*MMC 17.5 mg/m2 at 40°C for 90 minutes*Systemic CT protocol:*5-FU (400 mg/m2) + leucovorin (80 mg/m2) weekly for 26 wk |
| Yan *et al*[[62](#_ENREF_62)] | 1997-2007 | 50 | Case series (3) | CPM¥ | PCI < 10 20/50PCI 10-20 23/50PCI > 20 7/50 | CRS + HIPEC | Open coliseum technique | MMC 10-12.5 mg/m2 in 3L of 1.5% dextrose peritoneal dialysis solution for 90 min at 42°C |
| Elias *et al*[[54](#_ENREF_54)] | 1998-2003 | 96(48 *vs* 48) | Case-control(2-) | CPM¥ | *Treatment arm:*Limited 27/48Extended 21/48*Control arm:*Limited 26/48Extended 17/48Not recorded 5/48 | *Treatment arm:*CRS + HIPEC (*n* = 48) *Control arm:*Systemic CT only (*n* = 48) | - | *HIPEC protocol:*Oxaliplatin 460 mg/m2 in 2L/m2 at 43°C for 30 min. Before HIPEC (during CRS) patients received IV 5-FU 400 mg/m2 + leucovorin 20 mg/m2. *Systemic CT protocol:*Various regimens (5-FU based 46/48; Capecitabine based 1/48; Camptothecin 1/48)  |
| Varban *et al* [[43](#_ENREF_43)] | 1991-2007 | 142 | Case series (3) | CPM¥ | - | CRS + HIPEC | Closed technique | MMC 40 mg at 40.5-42.5°C for 120 min |
| Vaira *et al* [[44](#_ENREF_44)] | 1997-2008 | 40 | Case series(3) | CPM§ | PCI > 16 11/40PCI < 16 29/40 | CRS + HIPEC | Closed technique | Cisplatin (100 mg/m2) + MMC (16 mg/m2) at 41.5°C for 30 minOROxaliplatin (460 mg/m2) + IV 5-FU at 42°C for 30 minORMMC (35 mg/m2) at 40.5°C for 60 min |
| Glehen *et al*[[45](#_ENREF_45)] | 1989-2007 | 523 | Multi-centre case series (3) | CPM¥ | - | CRS + HIPEC and/or EPIC | Various techniques | *HIPEC protocol:*MMC (30-50 mg/m2) with or without cisplatin(50-100 mg/m2) delivered over 60-120 min at 41-42.5°COROxaliplatin (360-460 mg/m2) +/- irinotecan(100-200 mg/m2) +/- IV 5-FUand leucovorin delivered over 30 min at 43°C*EPIC protocol:*Abdominal cavity filled at the end of surgery with 1 L/m2Ringer lactate. EPIC lasted 5 days (POD 1-5);POD 1: MMC (10 mg/m2); POD 2-5: 5FU (600 mg/m2) |
| Franko *et al* [[55](#_ENREF_55)] | 2001-2007 | 105(67 *vs*. 38) | Case-control (2-)  | CPM§ | - | *Treatment arm:*CRS+ HIPEC (*n* = 67)*Control arm:* Systemic CT only (*n* = 38) | Closed abdomen technique | ***HIPEC protocol:***MMC 40mg for 100 min***Systemic CT protocol:***Chemotherapeutic regimen(s) not clearly described |
| Quenet *et al* [[46](#_ENREF_46)] | 1998-2007 | 146 | Case series (3) | CPM¥ | PCI < 10 69/146PCI 11-19 57/146PCI >20 20/146 | CRS + HIPEC | Closed technique | IV 5-FU (400 mg/m2) + leucovorin (20 mg/m2) followed by:i.p oxaliplatin (460 mg/m2) in 2L/m2 dextrose OR i.p oxaliplatin (300 mg/m2) + i.p irinotecan (200 mg/m2) in 2L/m2 dextrose |
| Cashin *et al*[[57](#_ENREF_57)] | 1993-2008 | 32(16 *vs* 16) | Case-control (2-) | CPM§ | *HIPEC group:*Mean PCI 14.4*EPIC group:*Mean PCI 13.2 | CRS + HIPEC (*n* = 16)CRS + EPIC(*n* =16) | *HIPEC:*Open coliseum technique*EPIC:*Closed technique | ***HIPEC protocol:***Oxaliplatin 460mg/m2 for 30 minutes at 41-42°C combined with IV 5-FU (450-500mg/m2) + leucovorin (25-30mg/m2)*EPIC protocol:*5-FU (500-600 mg/m2) + IV leucovorin (20-30 mg/m2) once daily for 86-day cycles  |
| Passot *et al*[[47](#_ENREF_47)] | 1991-2010 | 120 | Case series (3) | CPM¥ | Stage2 1-II 41/120Stage III-IV 79/120Mean PCI 8.2 | CRS + HIPEC | Closed technique | MMC + irinotecan or oxaliplatinExact dosing protocol not described |
| Hompes *et al*[[48](#_ENREF_48)] | 2004-2008 | 48 | Case series (3) | CPM§ | Median PCI 11 (1-22) | CRS + HIPEC | Open coliseum technique | IV folinic acid (20 mg/m2) + 5-FU (400 mg/m2) followed by i.p oxaliplatin (460 mg/m2) in 2L/m2 5% glucose solution at 41-42°C for 30 minutes  |
| Cashin *et al*[[56](#_ENREF_56)] | 1996-2010 | 151(69 *vs* 57) | Case control (2-) | CPM¥ | PCI 1-10 49/151PCI 11-20 45/151PCI 21-39 56/151 | CRS+ HIPEC(*n* = 69) CRS + EPIC(*n* = 57) | *HIPEC:*Open coliseum technique*EPIC:*Closed technique | *HIPEC protocol*MMC i.p (30mg/me) for 90 minutes at 41-42°C OR oxaliplatin (460mg/m2) i.p for 30 min at 41-42°C + IV 5-FU (400 mg/m2) and calcium folinate (60 mg/m2) OR oxaliplatin (360 mg/m2) i.p + irinotecan (360 mg/m2) for 30 minutes at 41-42°C + IV 5-FU (450-500 mg/m2) and calcium folinate (60 mg/m2)*EPIC protocol:*5-FU (500-600 mg/m2) i.p + IV leucovorin (60 mg/m2) once daily for 8 6-day cycles |
| Klaver *et al* [[49](#_ENREF_49)] | 1996-2010 | 24 | Case series (3) | CPM1δ | - | CRS+ HIPEC (12/24)CRS + EPIC(6/24)CRS + HIPEC + EPIC (6/24) | Open coliseum technique | HIPEC protocol:i.p chemotherapy (MMC or oxaliplatin; dosing not stated) at 42°C for 90 minutesEPIC protocol:5-FU (650-800 mg/m2 per day) in 1L 1.5% dextrose for 23 h on POD 1-5 |
| Turrini *et al* [[50](#_ENREF_50)] | 2004-2010 | 26 | Case series (3) | CPM1 | - | CRS + HIPEC | Open coliseum technique  | Oxaliplatin i.p (460 mg/m2) in 2L/m2 dextrose solution at 43°C for 30 minutes after 1 hour infusion of IV 5-FU (400 mg/m2) + leucovorin (20 mg/m2) |
| Haslinger *et a*l [[51](#_ENREF_51)] | 2003-2011 | 38 | Case series (3) | CPM§ | - | CRS+ HIPEC | Closed technique | MMC 40mg at temperature of 41°C for 60-120 min |
| Yonemura *et al* [[52](#_ENREF_52)] | 2004-2012 | 142 | Case series (3) | CPM¥ | - | CRS + HIPEC | - | MMC 20 mg/m2 + cisplatin 100 mg/m2 in $L saline at 42-43°C for 60 min  |

1Not stated clearly whether patients with distant metastases to other sites included/excluded. 2Gilly staging system; ¥ Cases with extra-abdominal metastatic involvement excluded (LN positive and liver metastasised cases included); δ all patients ≥ 70 years of age. PCI: Peritoneal cancer index; CRS: Cytoreductive surgery; EPIC: Early post-operative intraperitoneal chemotherapy; POD: Postoperative day; MMC: Mytomycin C; § Patients with distant metastases excluded; HIPEC: Hyperthermic intra-peritoneal chemotherapy.

**Table 2 Oncological outcome data**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Median FU (mth)** | **Pre-op CT** | **Post-op CT** | **Extent of cytoreduction/disease** | **1-year survival** | **2-year survival** | **3-year survival** | **4-year survival** | **5-year survival** | **Median survival (months)** | **Local/distant recurrence** |
| Portilla *et al*[[33](#_ENREF_33)] | 36.21  | 22% (regimen not stated) | 100% (regimen not stated) | CC0-CC1 (14/18; 64%)CC2-CC3 (4/18; 36%) PCI < 12 (10/18; 56%)PCI > 12 (8/18; 44%) | CC0-CC1 (91%)CC2-CC3 (43%)PC1 < 12 (N/A)PCI > 12 (N/A) | CC0-CC1 (64%)CC2-CC3 (14%)PCI < 12 (64%)PCI > 12 (14%) | - | - | - | Overall20 | - |
| Witkamp *et al*[[34](#_ENREF_34)] | 38 (26-52) | - | 72% (5-FU+ leucovorin)  | - | 82% | 45% | 23% | - | - | - | LR 28%DR 17%LR + DR 28% |
| Pilati *et al* [[35](#_ENREF_35)] | 14.5 (6-34) | 0% | - | CC0-1 34/34 | 68% | 31% | - | - | - | 18 | LR 59%DR 12%LR + DR 18% |
| Verwaal *et al* [[36](#_ENREF_36)] | 47.5 (1.3-88.3) | - | 15% (leucovorin) | R1 (54/106; 51%)R2a (37/106; 35%)R2b (15/106; 14%) | - | - | - | - | - | R1 11.1R2a 5.9R2b 3.7 | Unspecified recurrence 65% |
| Glehen *et al* [[37](#_ENREF_37)] | 59.5 | - | 68% (5-FU + irinotecan leucovorin) | CC0 (23/53; 43%)CC1 (11/53; 21%)CC2 (19/53; 36%) | CC0 85% CC1 46%CC2 24% | CC0 54%CC1 36%CC2 0% | - | - | CC0 22%CC1 9% | CC0 32.9CC1 12.5CC2 8.1 | Unspecified recurrence 19% |
| Mahteme *et al* [[53](#_ENREF_53)] | - | - | - | CC0 (11/18; 61%)CC1-2 (7/18; 39%) | - | CRS + EPIC 60%Control arm 10% | - | - | CRS + EPIC 28%Control arm 5% | CRS + EPIC overall 32; CC0 34.5 CC1-2 10 Control arm: 14 | - |
| Glehen *et al* [[38](#_ENREF_38)]  | 53 | 54% | 40% | CC0 (271/506; 54%)CC1 (106/506; 21%)CC2 (129/506; 25%) | CC0 87%CC1 79%CC2 38% | - | CC0 47%CC1 29%CC2 6% | - | CC0 31%CC1 15%CC2 0% | Males16.8Females21.6 | Unspecified recurrence 73%  |
| Shen *et al*[[39](#_ENREF_39)] | 15 (3-85) | 75% | - | R0 (13/77; 17%)R1 (24/77; 31%)R2a (11/77; 14%)R2b (9/77; 12%)R2c (20/77; 26%) | - | - | R0 69%R1 19%R2a 28%R2b 0%R2c 6% | - | R0 55%R1 19%R2a 14%R2b 0%R2c 0% | R0 N/RR1 17.8R2a 12.7R2b 4.1R2c 5.0 | Unspecified recurrence 68% |
| Cavaliere *et al*[[40](#_ENREF_40)]  | 16 | 72% | - | CC0 (102/120; 85%)CC1 (9/120; 7%)CC2-3 (9/120; 7%) | -  | - | Overall25.8%CC033.5% | - | - | 19 | - |
| Kianmanesh *et al*[[41](#_ENREF_41)] | - | 70% | 75% | - | - | 72% | - | 44% |  | 38.4 | - |
| Gusani *et al*[[42](#_ENREF_42)] | 35.9 (19-57.7) | - | - | - | 78% | 37% | 37% | - | - | 15.2 | - |
| Verwaal *et al*[[26](#_ENREF_26)]  | 96 (72-115) | - | - | R1 (22/54; 41%)R2a (23/54; 43%)R2b (9/54; 17%) | R1 95%R2a 65%R2b 22% | R1 80%R2a 20%R2b 12% | R1 58%R2a 10%R2b 0% | R1 52%R2a 10%R2c 0% | R1 45%R2a 10%R2c 0% | CRS + HIPEC22.2Systemic CT12.6 | - |
| Yan *et al*[[17](#_ENREF_17)] | 14 (1-56) | - | - | CC0 (41/50; 82%)CC1-3 (9/50; 8%) | CC0 85%CC1-3 51% | - | CC0 62%CC1-3 0% | - | - | CC0 37CC1-3 14 | Unspecified recurrence 34% |
| Elias *et al*[[54](#_ENREF_54)] | 95.7 | - | - | - | - | CRS + HIPEC81%Systemic CT65% | - | - | CRS + HIPEC51%Systemic CT13% | CRS + HIPEC62.7Systemic CT23.9 | - |
| Varban *et al*[[43](#_ENREF_43)] | 14.6 | - | - | - | - | HM 43.3%No HM 36.8% | - | HM 14.4%No HM 17.4% | - | HM 23No HM 15.8 | - |
| Vaira *et al*[[*44*](#_ENREF_44)*]* | - | 55% | - | CC0 (29/40; 73%)CC2 (11/40; 27%) | CC0 88%CC2 42% | - | - | - | - | Overall: 43CC0: 24CC2: 9.7 | - |
| Glehen *et al*[[45](#_ENREF_45)] | - | - | - | - | 81% | 58% | 39% | 34% | 28% | - | - |
| Franko *et al*[[55](#_ENREF_55)] | - | 100 | - | - | CRS + HIPEC90%Systemic CT55% | CRS + HIPEC65%Systemic CT35% | CRS + HIPEC50%Systemic CT12% | CRS + HIPEC42%Systemic CT10% | CRS + HIPEC25%Systemic CT7% | CRS + HIPEC34.7Systemic CT16.8 | - |
| Quenet *et al*[[46](#_ENREF_46)] | 48.5 | 100% | - | CC0 (132/146; 90%)CC1 (12/146; 8%)CC2 (2/146; 2%) | Overall92% | Overall72% | Overall55% | Overall50% | - | Overall41 | Unspecified recurrence 70% |
| Cashin *et al*[[56](#_ENREF_56)]  | HIPEC38EPIC66 | HIPEC81%EPIC44% | HIPEC38%EPIC38% | - | HIPEC100%EPIC80% | HIPEC group78%EPIC group48% | HIPEC group60%EPIC group25% | HIPEC group48%EPIC group17% | - | HIPEC group36.5EPIC group23.9 | - |
| Passot *et al*[[47](#_ENREF_47)] | 58.5 (1-183) | 75% | 64.3% | CC0 (93/120; 78%)CC1 (11/120; 9%)CC2 (16/120; 13%) | Overall77%  | Overall51% | - | - | Overall33% | Overall36.2 | - |
| Hompes *et al*[[48](#_ENREF_48)] | 22.7 (3.2-55.7)  | - | 62.5% | CC0 (48/48; 100%) | OS 98%DFS 66% | OS 89%DFS 46% | - | - | - | - | - |
| Cashin *et al*[[57](#_ENREF_57)] | 49 (0.5-100) | 31% | 18% | CC0 (97/151; 64%)CC1-3 (54/151; 36%) | HIPEC80%EPIC5% | HIPEC50%EPIC- | HIPEC 27%EPIC- | HIPEC 18%EPIC- | - | HIPEC34EPIC25 | - |
| Klaver *et al[*[49](#_ENREF_49)] | 10.5 (1-52) | - | - | CC0 (22/24; 92%)CC1 (2/24; 8%) | Overall83% | - | - | - | - | Overall35 | Unspecified recurrence 54% |
| Turrini *et al*[[50](#_ENREF_50)] | - | - | - | - | 100% | - | 51% | - | 37% | - | - |
| Haslinger *et al*[[51](#_ENREF_51)] | - | - | - | - | - | - | - | - | OS 38%PFS15% | - | - |
| Yonemura *et al*[51] | - | 77% | - | CC0 (108/142; 76%)CC1 34/142 (24%) | - | - | - | - | Overall 23.4%CC0 20%CC1 9.9% | Overall24.4CC0 25.9CC1 8  | - |

**1**Peritoneal cancer index (PCI) – Calculated by combining lesion size (0-3; 0 -no nodules present, 1 – nodule(s) ≤ 5mm diameter, 2–nodule(s) 5-50 mm in diameter, 3 – nodule(s) ≥ 50 mm in diameter) with the abdominopelvic regions affected[[33](#_ENREF_33)]. **2**Completeness of cytoreduction score (CCRS)[[33](#_ENREF_33)]; CC0 No visible tumour remaining; CC1 residual tumour deposits < 2.5 mm in diameter; CC2 residual tumour deposits 2.5-25 mm in diameter; CC3 residual tumour deposits > 25 mm in diameter.

**Table 3 Reported treatment-associated morbidity and mortality following multi-modality therapy for colorectal peritoneal metastase**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **N** | **Mortality****(%)** | **Overall morbidity (%)** | **No of bowel anastomoses** | **Intra-abdominal complications (%)** | **Extra-abdominal complications (%)** |
| Portilla *et al*[[33](#_ENREF_33)]  | 18 | 0 | No treatment-associated morbidity data provided |
| Witkamp *et al*[[34](#_ENREF_34)]  | 29 | 3 | 38 | 2 (0-5) | Postoperative bleeding (3)Bowel perforation (3)Bladder perforation (3)Return to theatre (17) Hydronephrosis requiring nephrostomy (7)Wound dehiscence (3)Prolonged chyle leak (3) | Grade I-II leucopenia (21)Grade III leucopenia (31)Peripheral neuropathy (10)Subclavian vein thrombosis (3) |
| Pilati *et al*[[35](#_ENREF_35)]  | 34 | 0 | 35 | - | Non-specified complications: Ozols’grade I (53%), grade II (9%), grade III (1%), grade IV (1%) | Haematological toxicity (12%)Pneumonia (12%)  |
| Verwaal *et al*[[36](#_ENREF_36)] | 106 | - | No treatment-associated morbidity data provided |
| Glehen *et al*[[37](#_ENREF_37)]  | 53 | 4 | 23 | 0.4 (0-4) | Return to theatre (4)Gastrointestinal fistula (8) | - |
| Mahteme *et al*[[53](#_ENREF_53)] | 18 | 0 | 61 | - | Severe nausea and vomiting (12%)Leak from drain (6%)Catheter-related problems (39%) | Transient neutropaenia (6%) |
| Glehen *et al*[[38](#_ENREF_38)]  | 506 | 4% | 22.9% | - | Re-operation (10.7%)Fistula (8.3%)Intra-abdominal abscess (1.8%)Urinary fistula (1%) | Haematological toxicity (2.4%)Systemic sepsis (2%)Cardiorespiratory complications (3.5%) |
| Shen *et al*[[39](#_ENREF_39)] | 77 | 12 | 30 | - | Bowel perforation (3%) | Haematological toxicity (19%) |
| Cavaliere *et al*[[40](#_ENREF_40)]  | 120 | 3.3 | 22.5 | - | Perforation (5%)Anastomotic leak (3.3%)Infection (3.3%) |  |
| Kianmanesh *et al*[[41](#_ENREF_41)] | 43 | 2.3 | 39 | - | Deep abscess (14%)Intestinal fistula (9%)Delayed gastric emptying (9%)Re-operation (4%) | Pleural effusion (12%)Renal failure (7%)Superficial wound infection (12%) |
| Gusani *et al*[[42](#_ENREF_42)]  | 28 | 0 | 56.5 | - | Re-operation (8%)Anastomotic leak (8%)Intra-abdomoninal abscess (4%)Wound dehiscence (4%)Enterocutaneous fistula (2%) | Systemic sepsis (4%) |
| Verwaal *et al*[[26](#_ENREF_26)]  | 54 | - | No treatment-associated morbidity data provided |
| Yan *et al*[[17](#_ENREF_17)] | 50 | 0 | 46 | - | Small bowel obstruction (12%)Fistula (10%)Intra-abdominal abscess (10%)Perforation (4%) | Pleural effusion (34%)Pneumonia (4%) |
| Elias *et al*[[54](#_ENREF_54)]  | 48 | - | No treatment-associated morbidity data provided |
| Varban *et al*[[43](#_ENREF_43)]  | 142 | CPM with HM7.1%CPM with no HM7.7% | CPM with HM57.1%CPM with no HM40.1% | - | CPM with HMBowel leak (11%)Wound infection (11%)Pancreatic fistula (11%)Ileus (11%)CPM with no HMBowel leak (5%)Wound infection (5%)Ileus (5%)Enterocutaneous fistula (1%) | CPM with HMPneumonia (7%)Neutropaenia (7%)DVT (7%)CPM with no HMPneumonia (6%)Neutropaenia (8%)AF (3%)Thrombocytopaenia (2%) |
| Vaira *et al*[[44](#_ENREF_44)] | 40 | 2.5 | 55 | 0 (17.5)1(55)2 (27.5) | Fistula (10%)Abdominal abscess (7.5%) | Haematological toxicity (12.5%)Pleural effusion (22.5%)Superficial wound infection (12.5%) |
| Glehen *et al*[[45](#_ENREF_45)]  | 523 | - | Not specifically provided for patients undergoing procedures for CPM |
| Franko *et al*[54] | 105 | - | No treatment-associated morbidity data provided |
| Quenet *et al*[[46](#_ENREF_46)]  | 146 | 4.1 | 47.2 | - | GI fistula (4.8%)Urinary fistula (1.4%)Abdominal abscess (2.7%)Reoperation (11.6%) | - |
| Cashin *et al*[[57](#_ENREF_57)] | 32 | *HIPEC group;*6%*EPIC group;*6% | *HIPEC group;*37%*EPIC group;*19% | - | *HIPEC group;*Reoperation (12%)*EPIC group;*Reoperation (6%) | *HIPEC group;*CVA (6%)*EPIC group;*- |
| Passot *et al*[[47](#_ENREF_47)] | 120 | 3.8% | 21.8% | - | Reoperation (13.3%)Fistula (7.5%) |  |
| Hompes *et al*[[48](#_ENREF_48)]  | 48 | 0 | 52.1 | 1 (0-6) | Prolonged ileus (23%)Anastomotic leakage (10.4%)Bleeding (6.3%)Bowel perforation (2.1%)Fistula (2.1%)Abscess (2.1%)Reoperation (20.8%) | Pulmonary (12.5%)Cardiac (2.1%)Urological (12.5%)Haematological (2.5) |
| Cashin *et al*[[56](#_ENREF_56)] | 151 | *HIPEC group:*4%*EPIC group:*3% | *HIPEC group:*41%*EPIC group:*30% | - | - | - |
| Klaver *et al*[[49](#_ENREF_49)] | 24 | 0 | 62 | - | Prolonged ileus (21%)Intra-abdominal collection requiring drainage (21%)Fistula (4%)Splenic infarction (4%) | Superficial wound infection (4%)Cardiorespiratory complications (38%)Urological (4%) |
| Turrini *et al*[[50](#_ENREF_50)]  | 26 | 0 | 33 | - | Fistula (10%)Delayed gastric emptying (10%) | Haematological toxicity (10%) |
| Haslinger *et al*[[51](#_ENREF_51)]  | 38 | - | Not specifically provided for patients undergoing procedures for CPM |
| Yonemura *et al*[[52](#_ENREF_52)] | 142 | 0.7% | 42.9% | - | - | - |

CPM: Colorectal peritoneal metastase; HM: Hepatic metastasis.